The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Sep. 26, 9:51 AM

Slide #25. Immune Design Corp. Secondary Offering

Company: Immune Design Corp. (NASDAQ:IMDZ)
Date announced: 9/14/2016
Shares Offered: 4,800,000
Date of Pricing: 9/15/2016
Price Per Share: $6.25
Secondary Offering Details: Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Immune Design. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. -updated 9/15- Immune Design Corp. (Nasdaq:IMDZ) announced today the pricing of an underwritten public offering of 4,800,000 shares of its common stock at a price to the public of $6.25 per share. All of the shares of common stock are being offered by Immune Design. Proceeds to Immune Design from this offering are expected to be approximately $30.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on September 20, 2016, subject to customary closing conditions. Jefferies LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering. Immune Design has granted the underwriters a 30-day option to purchase up to 720,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Immune Design is a clinical stage immuno-therapy company with in vivo approaches designed to enable the body's immune system to fight disease. Co. has developed its technologies to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer. Co. is developing multiple product candidates from its two discovery platforms, ZVex™ and GLAAS™. Co.'s primary product candidates, CMB305 and G100, utilize multiple immuno-oncology approaches and are in multiple Phase 1and Phase 2 trials. In addition, Co. has licensed the right to use the GLAAS platform in specific infectious disease and allergy indications.

IMDZ SEC Filing Email Alerts Service

Open the IMDZ Page at The Online Investor »

Company Name:  Immune Design Corp
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding IMDZ:  17
Total Market Value Held by ETFs:  $4.68M
Total Market Capitalization:  $152.00M
% of Market Cap. Held by ETFs:  3.08%

Open the IMDZ Page at The Online Investor (in a new window) »

September 26, 2016    9:51 AM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
92nd percentile
(ranked higher than approx. 92% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.